Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance
Eligible age
18+ yrs
Accepts
Men
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Prostate cancer is the most commonly diagnosed cancer in men. However, there is a wide range in prognosis determined by a host of factors. This study will evaluate the feasibility of guiding therapeutic intervention electronically facilitated symptom and disease monitoring in patients being followed on Active Surveillance. Additionally, we will develop a tissue and data resource to support discovery and hypothesis generation to evaluate germline and/or somatic alterations in relation to cancer-specific and overall outcomes..
Sponsor: M.D. Anderson Cancer Center
You may qualify if…
- ✓ 1. Patients will have histologic diagnosis of adenocarcinoma of the prostate within 24 months of study entry.
- ✓ 2. Patient must meet at least one of the following clinical indications for AS: National Comprehensive Cancer Network (NCCN) very low risk or low risk prostate cancer meeting consensus guidelines for AS; NCCN intermediate-risk prostate cancer requesting AS (per patient and clinician shared decision making); or have severe medical comorbidities (defined as CCI estimated 10-year survival \< 50% and agreed by treating clinician) with high- or very high-risk localized prostate cancer.
- ✓ 3. Patients must agree to comply with the surveillance schedule.
- ✓ 4. Patients must be over 18 years of age
- ✓ 5. Written informed consent
- ✓ 6. Patients must be fluent in the English language to participate in the patient report outcome and symptoms monitoring portion of the trial.
You may not qualify if…
- ✕ 1. Patients are ineligible if they choose not to share their medical data for research purposes.
- ✕ 2. Prior radiation therapy for treatment of the primary tumor.
- ✕ 3. Planned concomitant hormonal therapy, chemotherapy, or radiation therapy while on protocol
Where it's recruiting
Houston
Source: ClinicalTrials.gov · NCT05840484 · last updated 2026-08-10